Met Life Investment Management, LLC Kymera Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 25,888 shares of KYMR stock, worth $1.09 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,888
Previous 25,888 -0.0%
Holding current value
$1.09 Million
Previous $772,000 58.68%
% of portfolio
0.01%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$29.85 - $39.42 $153,249 - $202,382
5,134 Added 24.74%
25,888 $772,000
Q1 2024

May 14, 2024
BUY
$22.9 - $43.57 $475,266 - $904,251
20,754 New
20,754 $834,000
Q2 2023

Apr 29, 2024
BUY
$22.4 - $34.92 $447,216 - $697,177
19,965 New
19,965 $458,000
Q1 2023

May 09, 2024
BUY
$24.84 - $38.75 $495,930 - $773,643
19,965 New
19,965 $592 Million
Q4 2022

May 10, 2024
SELL
$19.57 - $30.92 $44,482 - $70,281
-2,273 Reduced 10.22%
19,965 $498,000
Q4 2022

Mar 22, 2023
SELL
$19.57 - $30.92 $44,482 - $70,281
-2,273 Reduced 10.22%
19,965 $498,000
Q4 2022

Feb 15, 2023
SELL
$19.57 - $30.92 $44,482 - $70,281
-2,273 Reduced 10.22%
19,965 $498,000
Q3 2022

May 10, 2024
BUY
$20.91 - $34.27 $62,939 - $103,152
3,010 Added 15.65%
22,238 $484,000
Q3 2022

Jun 14, 2023
BUY
$20.91 - $34.27 $47,528 - $77,895
2,273 Added 11.38%
22,238 $484,000
Q3 2022

Mar 22, 2023
BUY
$20.91 - $34.27 $62,939 - $103,152
3,010 Added 15.65%
22,238 $484,000
Q3 2022

Nov 14, 2022
BUY
$20.91 - $34.27 $62,939 - $103,152
3,010 Added 15.65%
22,238 $484,000
Q2 2022

Jun 20, 2023
SELL
$14.13 - $42.55 $10,413 - $31,359
-737 Reduced 3.69%
19,228 $378,000
Q1 2022

May 10, 2024
BUY
$35.3 - $64.68 $678,748 - $1.24 Million
19,228 New
19,228 $813,000
Q1 2022

Jun 20, 2023
SELL
$35.3 - $64.68 $26,016 - $47,669
-737 Reduced 3.69%
19,228 $813,000
Q1 2022

Mar 22, 2023
BUY
$35.3 - $64.68 $246,429 - $451,531
6,981 Added 57.0%
19,228 $813,000
Q1 2022

May 12, 2022
BUY
$35.3 - $64.68 $246,429 - $451,531
6,981 Added 57.0%
19,228 $814,000
Q4 2021

Jun 21, 2023
SELL
$49.91 - $65.56 $385,205 - $505,992
-7,718 Reduced 38.66%
12,247 $777,000
Q3 2021

May 17, 2024
BUY
$47.8 - $66.66 $50,811 - $70,859
1,063 Added 9.5%
12,247 $719,000
Q3 2021

Jun 21, 2023
SELL
$47.8 - $66.66 $368,920 - $514,481
-7,718 Reduced 38.66%
12,247 $719,000
Q3 2021

Mar 22, 2023
BUY
$47.8 - $66.66 $50,811 - $70,859
1,063 Added 9.5%
12,247 $719,000
Q3 2021

Nov 15, 2021
BUY
$47.8 - $66.66 $50,811 - $70,859
1,063 Added 9.5%
12,247 $719,000
Q2 2021

May 17, 2024
BUY
$31.08 - $51.95 $206,215 - $344,688
6,635 Added 145.86%
11,184 $542,000
Q2 2021

Jun 21, 2023
SELL
$31.08 - $51.95 $272,913 - $456,172
-8,781 Reduced 43.98%
11,184 $542,000
Q2 2021

Mar 22, 2023
BUY
$31.08 - $51.95 $206,215 - $344,688
6,635 Added 145.86%
11,184 $542,000
Q2 2021

Aug 16, 2021
BUY
$31.08 - $51.95 $206,215 - $344,688
6,635 Added 145.86%
11,184 $542,000
Q1 2021

May 17, 2024
SELL
$35.64 - $85.46 $577,546 - $1.38 Million
-16,205 Reduced 78.08%
4,549 $176,000
Q1 2021

Jun 26, 2023
SELL
$35.64 - $85.46 $549,426 - $1.32 Million
-15,416 Reduced 77.22%
4,549 $177 Million
Q4 2020

May 24, 2024
SELL
$28.07 - $87.83 $454,874 - $1.42 Million
-16,205 Reduced 78.08%
4,549 $282,000
Q4 2020

Jun 22, 2023
SELL
$28.07 - $87.83 $432,727 - $1.35 Million
-15,416 Reduced 77.22%
4,549 $282,000
Q4 2020

Mar 22, 2023
SELL
$28.07 - $87.83 $432,727 - $1.35 Million
-15,416 Reduced 77.22%
4,549 $282,000
Q4 2020

Feb 16, 2021
BUY
$28.07 - $87.83 $127,690 - $399,538
4,549 New
4,549 $282,000

Others Institutions Holding KYMR

# of Institutions
184
Shares Held
64.4M
Call Options Held
50.6K
Put Options Held
81.7K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.3B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email